FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308796736> ?p ?o ?g. }

• W4308796736 endingPage "e2241622" @default.
• W4308796736 startingPage "e2241622" @default.
• W4308796736 abstract "Minimal data are available regarding the postdischarge treatment of multisystem inflammatory syndrome in children (MIS-C).To evaluate clinical characteristics associated with duration of postdischarge glucocorticoid use and assess postdischarge clinical course, laboratory test result trajectories, and adverse events in a multicenter cohort with MIS-C.This retrospective cohort study included patients with MIS-C hospitalized with severe illness and followed up for 3 months in an ambulatory setting. Patients younger than 21 years who were admitted between May 15, 2020, and May 31, 2021, at 13 US hospitals were included. Inclusion criteria were inpatient treatment comprising intravenous immunoglobulin, diagnosis of cardiovascular dysfunction (vasopressor requirement or left ventricular ejection fraction ≤55%), and availability of complete outpatient data for 3 months.Glucocorticoid treatment.Main outcomes were patient characteristics associated with postdischarge glucocorticoid treatment, laboratory test result trajectories, and adverse events. Multivariable regression was used to evaluate factors associated with postdischarge weight gain (≥2 kg in 3 months) and hyperglycemia during illness.Among 186 patients, the median age was 10.4 years (IQR, 6.7-14.2 years); most were male (107 [57.5%]), Black non-Hispanic (60 [32.3%]), and Hispanic or Latino (59 [31.7%]). Most children were critically ill (intensive care unit admission, 163 [87.6%]; vasopressor receipt, 134 [72.0%]) and received inpatient glucocorticoid treatment (178 [95.7%]). Most were discharged with continued glucocorticoid treatment (173 [93.0%]); median discharge dose was 42 mg/d (IQR, 30-60 mg/d) or 1.1 mg/kg/d (IQR, 0.7-1.7 mg/kg/d). Inpatient severity of illness was not associated with duration of postdischarge glucocorticoid treatment. Outpatient treatment duration varied (median, 23 days; IQR, 15-32 days). Time to normalization of C-reactive protein and ferritin levels was similar for glucocorticoid duration of less than 3 weeks vs 3 or more weeks. Readmission occurred in 7 patients (3.8%); none was for cardiovascular dysfunction. Hyperglycemia developed in 14 patients (8.1%). Seventy-five patients (43%) gained 2 kg or more after discharge (median 4.1 kg; IQR, 3.0-6.0 kg). Inpatient high-dose intravenous and oral glucocorticoid therapy was associated with postdischarge weight gain (adjusted odds ratio, 6.91; 95% CI, 1.92-24.91).In this multicenter cohort of patients with MIS-C and cardiovascular dysfunction, postdischarge glucocorticoid treatment was often prolonged, but clinical outcomes were similar in patients prescribed shorter courses. Outpatient weight gain was common. Readmission was infrequent, with none for cardiovascular dysfunction. These findings suggest that strategies are needed to optimize postdischarge glucocorticoid courses for patients with MIS-C." @default.
• W4308796736 created "2022-11-15" @default.
• W4308796736 creator A5002003969 @default.
• W4308796736 creator A5002172790 @default.
• W4308796736 creator A5002367577 @default.
• W4308796736 creator A5002868596 @default.
• W4308796736 creator A5003818704 @default.
• W4308796736 creator A5008543218 @default.
• W4308796736 creator A5009301455 @default.
• W4308796736 creator A5009536548 @default.
• W4308796736 creator A5012772635 @default.
• W4308796736 creator A5015250606 @default.
• W4308796736 creator A5015856020 @default.
• W4308796736 creator A5017214251 @default.
• W4308796736 creator A5019789115 @default.
• W4308796736 creator A5019807753 @default.
• W4308796736 creator A5020922277 @default.
• W4308796736 creator A5022979690 @default.
• W4308796736 creator A5027374619 @default.
• W4308796736 creator A5027686520 @default.
• W4308796736 creator A5027963180 @default.
• W4308796736 creator A5029115276 @default.
• W4308796736 creator A5030642727 @default.
• W4308796736 creator A5031269039 @default.
• W4308796736 creator A5031874573 @default.
• W4308796736 creator A5038521422 @default.
• W4308796736 creator A5041157115 @default.
• W4308796736 creator A5041643399 @default.
• W4308796736 creator A5042298247 @default.
• W4308796736 creator A5045499174 @default.
• W4308796736 creator A5045670196 @default.
• W4308796736 creator A5048349218 @default.
• W4308796736 creator A5048707971 @default.
• W4308796736 creator A5050194774 @default.
• W4308796736 creator A5051589775 @default.
• W4308796736 creator A5052251928 @default.
• W4308796736 creator A5053578480 @default.
• W4308796736 creator A5055459640 @default.
• W4308796736 creator A5057439250 @default.
• W4308796736 creator A5060504843 @default.
• W4308796736 creator A5065214874 @default.
• W4308796736 creator A5065907654 @default.
• W4308796736 creator A5071618232 @default.
• W4308796736 creator A5072000779 @default.
• W4308796736 creator A5079695343 @default.
• W4308796736 creator A5080115379 @default.
• W4308796736 creator A5081936870 @default.
• W4308796736 creator A5085957474 @default.
• W4308796736 creator A5087750390 @default.
• W4308796736 creator A5088298720 @default.
• W4308796736 creator A5089135490 @default.
• W4308796736 creator A5089324852 @default.
• W4308796736 creator A5091740212 @default.
• W4308796736 date "2022-11-11" @default.
• W4308796736 modified "2023-09-29" @default.
• W4308796736 title "Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children" @default.
• W4308796736 cites W1985527818 @default.
• W4308796736 cites W1993436135 @default.
• W4308796736 cites W2102647537 @default.
• W4308796736 cites W2109450728 @default.
• W4308796736 cites W2331124118 @default.
• W4308796736 cites W2582026775 @default.
• W4308796736 cites W2599076725 @default.
• W4308796736 cites W2604027935 @default.
• W4308796736 cites W2782847795 @default.
• W4308796736 cites W3022798884 @default.
• W4308796736 cites W3024521558 @default.
• W4308796736 cites W3032824264 @default.
• W4308796736 cites W3034016318 @default.
• W4308796736 cites W3037731101 @default.
• W4308796736 cites W3038003713 @default.
• W4308796736 cites W3043906604 @default.
• W4308796736 cites W3080556470 @default.
• W4308796736 cites W3087313970 @default.
• W4308796736 cites W3087378474 @default.
• W4308796736 cites W3088685472 @default.
• W4308796736 cites W3091733053 @default.
• W4308796736 cites W3112078636 @default.
• W4308796736 cites W3126451306 @default.
• W4308796736 cites W3132267494 @default.
• W4308796736 cites W3166141498 @default.
• W4308796736 cites W3171562490 @default.
• W4308796736 cites W3195688352 @default.
• W4308796736 cites W4205682741 @default.
• W4308796736 cites W4206755077 @default.
• W4308796736 cites W4210430000 @default.
• W4308796736 cites W4213181816 @default.
• W4308796736 cites W4213182075 @default.
• W4308796736 cites W4220683763 @default.
• W4308796736 cites W4221052348 @default.
• W4308796736 cites W4233237648 @default.
• W4308796736 cites W4280488375 @default.
• W4308796736 cites W4282942286 @default.
• W4308796736 cites W4288992566 @default.
• W4308796736 cites W4292229870 @default.
• W4308796736 doi "https://doi.org/10.1001/jamanetworkopen.2022.41622" @default.
• W4308796736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36367723" @default.
• W4308796736 hasPublicationYear "2022" @default.

• next